Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Postmenopausal women with osteoporosis, defined as low bone mineral density (BMD T-score at the total hip or femoral neck of ≤ -2.50)~Exclusion Criteria:~* BMD T-score of ≤ -3.50 at the total hip or femoral neck~* History of hip fracture~* Any severe or more than 2 moderate vertebral fractures, as assessed by the central imaging based on lateral spine x-rays~* Use of agents affecting bone metabolism~* History of metabolic or bone disease (except osteoporosis)~* Vitamin D insufficiency (vitamin D repletion and rescreening is permitted)~* Current hyper- or hypocalcemia~* Current, uncontrolled hyper- or hypothyroidism~* Current, uncontrolled hyper- or hypoparathyroidism

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Romosozumab (Type: EXPERIMENTAL): Participants received 210 mg romosozumab subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).